Secondary analysis of a phase 3 trial in 7769 people with HIV: pitavastatin vs placebo lowered LDL by an estimated 30 mg/dL (30%) at 12 months; 30% lower LDL was associated with 20% lower MACE risk (HR 0.80), with an estimated 68% of benefit mediated through LDL.
Secondary analysisn = 7,769
Umbleja et al. Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis